ANRO
Alto Neuroscience, Inc.
NYSE · Healthcare · Biotechnology · US
$22.28
−5.07%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -30.5%
- EBIT
- +163.3%
- EPS
- -3.8%
- Free cash flow
- -21.6%
- Operating cash flow
- -24.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +60.7%
- EPS
- -20.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- +3.5%
- EBIT
- +3.3%
- Net income
- -2.9%
- EPS
- +12.4%
- Free cash flow
- -4.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026